EPAT 2001

1 Treatments

**Studied treatment**  micronized 17beta-estradiol (1 mg/d)

**Control treatment**  placebo

Concomittant treatments  -

**Age (years)**  61y

**Age (years)**  -

2 Patients

**Patients**  postmenopausal women 45 years of age or older without preexisting cardiovascular disease and with low-density lipoprotein cholesterol levels of 3.37 mmol/L or greater (>=130 mg/dL)

**Inclusion criteria**  postmenopausal (serum estradiol level < 73.4 pmol/L [<20 pg/mL]), 45 years of age or older, and had a low-density lipoprotein (LDL) cholesterol level of 3.37 mmol/L or greater (>=130 mg/dL)

**Exclusion criteria**  breast or gynecologic cancer in the past 5 years or identified during screening; previously use of HRT for more than 10 years or HRT within 1 month; five or more hot flushes daily that interfered with daily activity, diastolic blood pressure greater than 110 mm Hg, untreated thyroid disease, life-threatening disease with a survival prognosis of less than 5 years, total triglyceride level of 4.52 mmol/L or greater (>=400 mg/dL), high-density lipoprotein (HDL) cholesterol level less than 0.78 mmol/L (<30 mg/dL), or serum creatinine concentration greater than 221 /umol/L (>=2.5 mg/dL); current smokers

**type of prevention**  primary prevention

**diabetes (%)**  3%

**hypertension (%)**  -

**hyperlipidemia (%)**  -

**BMI (kg/m²)**  29

**Hysterectomy (%)**  -

**Oophorectomy (%)**  -

3 Methods

**Blinding**  double-blind
**Design**  Parallel groups

**Centers**  single center

**Geographical area**  USA

**Sizes**  111/111

### 4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>stroke</td>
<td>2/111</td>
<td>0/111</td>
<td>5.00</td>
<td>[0.24; 105.36]</td>
</tr>
<tr>
<td>venous thromboembolism</td>
<td>-/111</td>
<td>-/111</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>PE</td>
<td>-/111</td>
<td>-/111</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all cause death</td>
<td>0/111</td>
<td>1/111</td>
<td>0.33</td>
<td>[0.01; 8.27]</td>
</tr>
<tr>
<td>CV events</td>
<td>3/111</td>
<td>2/111</td>
<td>1.40</td>
<td>[0.27; 7.25]</td>
</tr>
<tr>
<td>Cv death</td>
<td>0/111</td>
<td>1/111</td>
<td>0.33</td>
<td>[0.01; 8.27]</td>
</tr>
<tr>
<td>Coronary events (CHD)</td>
<td>-/111</td>
<td>-/111</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>non fatal MI</td>
<td>1/111</td>
<td>1/111</td>
<td>1.00</td>
<td>[0.10; 9.76]</td>
</tr>
</tbody>
</table>

### 5 References